Synonyms: example 1 [WO2016094821A2]
rezivertinib is an approved drug
Compound class:
Synthetic organic
Comment: The chemical structure submitted to the WHO for INN rezivertinib, is identical to the structure of example 1 that is claimed in patent WO2016094821A2 by Beta Pharma [1]. This patent claims novel EGFR inhibitors that are active against mutated EGFRs that are found in cancers, i.e. third generation EGFR inhibitors. From Beta Pharma's declared pipeline, example 1 is likely to be BPI-7711, which is being investigated for the treatment of EGFRT790M-mutant non-small cell lung cancer. We await formal name>structure confirmation. Experimental evidence in WO2016094821A2 indicates that example 1 is orally bioavailable.
|
|
References |
1. Peng J, Costanzo MJ, Greco MN, Green MA, Wilde VL, Zhang D. (2016)
Substituted 2-anilinopyrimidine derivatives as EGFR modulators. Patent number: WO2016094821A2. Assignee: Beta Pharma, Inc.. Priority date: 11/12/2014. Publication date: 16/06/2016. |